These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37094323)

  • 1. Editorial: improvement of cardiovascular risk factor control in patients with type 2 diabetes and nonalcoholic fatty liver disease-time for action! Authors' reply.
    Zhang X; Wong GL; Wong VW; Yip TC
    Aliment Pharmacol Ther; 2023 May; 57(10):1172-1173. PubMed ID: 37094323
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: improvement of cardiovascular risk factor control in patients with type 2 diabetes and nonalcoholic fatty liver disease-time for action!
    Caussy C
    Aliment Pharmacol Ther; 2023 May; 57(10):1170-1171. PubMed ID: 37094300
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in non-alcoholic fatty liver disease-simply associated or more complicated? Authors' reply.
    Park JG; Jung J; Loomba R
    Aliment Pharmacol Ther; 2021 Jun; 53(11):1230-1231. PubMed ID: 33961702
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease is a risk factor for cardiovascular and cardiac diseases: further evidence that a holistic approach to treatment is needed.
    Byrne CD; Targher G
    Gut; 2022 Sep; 71(9):1695-1696. PubMed ID: 34509980
    [No Abstract]   [Full Text] [Related]  

  • 5. Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. Authors' reply.
    Waluś-Miarka M; Kapusta M; Miarka P; Trojak A; Idzior-Waluś B; Małecki MT
    Pol Arch Intern Med; 2019 Sep; 129(9):649-650. PubMed ID: 31566589
    [No Abstract]   [Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease.
    Vanjiappan S; Hamide A; Ananthakrishnan R; Periyasamy SG; Mehalingam V
    Diabetes Metab Syndr; 2018 Jul; 12(4):479-482. PubMed ID: 29402657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk.
    Caussy C; Aubin A; Loomba R
    Curr Diab Rep; 2021 Mar; 21(5):15. PubMed ID: 33742318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial: re-thinking cardiovascular risk factors in NAFLD with advanced fibrosis? Authors' reply.
    Henson JB; Corey KE
    Aliment Pharmacol Ther; 2020 May; 51(10):988-989. PubMed ID: 32338780
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Mantovani: "Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes".
    Zaccardi F; Morrison AE; Khunti K; Davies MJ
    Liver Int; 2019 Apr; 39(4):780-781. PubMed ID: 30615269
    [No Abstract]   [Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease and cardiovascular risk in severely obese adolescents.
    Sert A
    Acta Diabetol; 2021 Jan; 58(1):121-122. PubMed ID: 32740703
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
    Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF
    Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.
    Duell PB; Welty FK; Miller M; Chait A; Hammond G; Ahmad Z; Cohen DE; Horton JD; Pressman GS; Toth PP;
    Arterioscler Thromb Vasc Biol; 2022 Jun; 42(6):e168-e185. PubMed ID: 35418240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non-alcoholic fatty liver disease - authors' reply.
    Mullish BH; Forlano R; Abeles RD; Thursz MR; Manousou P
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1093-1094. PubMed ID: 30920045
    [No Abstract]   [Full Text] [Related]  

  • 14. Liver Stiffness Severity is Associated With Increased Cardiovascular Risk in Patients With Type 2 Diabetes.
    Mangla N; Ajmera VH; Caussy C; Sirlin C; Brouha S; Bajwa-Dulai S; Madamba E; Bettencourt R; Richards L; Loomba R
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):744-746.e1. PubMed ID: 31100460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial: increasing burden of nonalcoholic fatty liver disease-a call to action. Authors' reply.
    Estes C; Chan HLY; Chien RN; Chuang WL; Fung J; Goh GB; Hu TH; Huang JF; Jang BK; Jun DW; Kao JH; Lee JW; Lin HC; Razavi-Shearer K; Seto WK; Wong GL; Wong VW; Razavi H
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1430-1432. PubMed ID: 32445526
    [No Abstract]   [Full Text] [Related]  

  • 16. Update on cardiovascular risk in nonalcoholic fatty liver disease.
    Johnston MP; Patel J; Byrne CD
    Curr Opin Cardiol; 2021 Jul; 36(4):478-486. PubMed ID: 34059612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study.
    Ichikawa K; Miyoshi T; Osawa K; Miki T; Toda H; Ejiri K; Yoshida M; Nanba Y; Yoshida M; Nakamura K; Morita H; Ito H
    Cardiovasc Diabetol; 2021 Jan; 20(1):8. PubMed ID: 33413363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease.
    Wijarnpreecha K; Aby ES; Ahmed A; Kim D
    Clin Mol Hepatol; 2021 Apr; 27(2):221-235. PubMed ID: 33317243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter: role of mean platelet volume levels in the prediction of major acute cardiovascular events in patients with non-alcoholic fatty liver disease-authors' reply.
    Mullish BH; Forlano R; Abeles RD; Thursz MR; Manousou P
    Aliment Pharmacol Ther; 2019 Nov; 50(10):1140-1141. PubMed ID: 31657474
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.